Prof. Dr. med. Elisabeth Heßmann

Further involvements

• Th, 15/02

  14:40 – 14:50 8 Min. 2 Min.

  • Oral presentation
  • O07

  Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response via AP1 dichotomy in pancreatic cancer

   Tumour microenvironment, epigenetics and stem cells
• Th, 15/02

  16:25 – 16:30 3 Min. 2 Min.

  • ePoster presentation
  • P17

  Characterizing the impact of MAZ and cJUN in regulating inflammatory- and tumor- promoting gene programs in ARID1A-deficient PDAC subtypes

   Pancreatic cancer
• Fr, 16/02

  14:45 – 14:50 3 Min. 2 Min.

  • ePoster presentation
  • P29

  Distinct TP53 missense mutations induce diverging pathways to foster pancreatic cancer aggressiveness

   Pancreatic cancer
• Fr, 16/02

  16:25 – 16:35 8 Min. 2 Min.

  • Oral presentation
  • O33

  Integration of biological characteristics of pancreatic cancer PDX and CDX models with clinical annotations of the donor patients

   Pancreatic cancer
• Sa, 17/02

  10:05 – 10:10 3 Min. 2 Min.

  • ePoster presentation
  • P45

  KRASG12C inhibitor-based combination therapies for pancreatic cancer: Insights from drug screening

   Pancreatic cancer
• Sa, 17/02

  10:15 – 10:20 3 Min. 2 Min.

  • ePoster presentation
  • P58

  Characterization of the plasticity of primary PDAC cells in an orthotopic in vivo model

   Pancreatic cancer
• Sa, 17/02

  10:35 – 10:40 3 Min. 2 Min.

  • ePoster presentation
  • P62

  GSK3ß;NFATc1 Subtype-Specific targeting in pancreatic cancer

   Pancreatic cancer
• Sa, 17/02

  13:50 – 14:00 8 Min. 2 Min.

  • Oral presentation
  • O61

  Molecular characterization of the cell-intrinsic mechanisms driving NFATc1:STAT3-mediated PDAC tumor heterogeneity

   Pancreatic cancer